Vermont AG investigates 10 drugmakers over price hikes

The Vermont attorney general's office has asked 10 pharmaceutical companies to defend their prices for certain products, reports VT Digger.

Under the state's new drug price transparency law, the Green Mountain Care Board  used state Medicaid claims data to assemble a list of drugs whose sticker prices have gone up by 15 percent in one year, or by 50 percent in five years.

As a result of GMCB's investigation, the attorney general's office has asked 10 pharmaceutical companies by Oct. 1 to submit information that justifies their prescription price increases to the state.

Below are the 10 drugs being investigated and their rate-of-increase during the last five years. They have been listed alphabetically.

1. Abilify — 55.3 percent
2. Crestor —75.9 percent
3. Doxycycline hyclate —4,787.6 percent
4. Enbrel —92.7 percent
5. EpiPpen — 205.5 percent
6. Humira — 113.8 percent
7. Lantus — 89.8 percent
8. Latuda — 99.7 percent
9. Permethrin — N/A
10. Prevacid — 103.3 percent